Ion Beam Applications SA
Ion Beam Applications SA (IBAB.BR) Stock Competitors & Peer Comparison
See (IBAB.BR) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| IBAB.BR | €12.88 | -0.62% | 371M | 21.83 | €0.58 | +1.90% |
| PHIA.AS | €23.55 | -0.72% | 22.3B | 25.25 | €0.93 | +3.62% |
| ALERS.PA | €22.15 | +0.00% | 223M | 100.68 | €0.22 | N/A |
| ALMDT.PA | €4.41 | +0.80% | 161.7M | -3.71 | -€1.16 | N/A |
| ALCOR.PA | €35.10 | +0.29% | 154.5M | -234.00 | -€0.15 | N/A |
| GBT.PA | €9.78 | +1.03% | 123.5M | -1.10 | -€8.93 | N/A |
| EAPI.PA | €1.27 | +1.52% | 119.2M | -0.96 | -€1.31 | N/A |
| AFME.PA | €2.81 | +0.00% | 110.4M | -7.81 | -€0.36 | N/A |
| SEQUA.BR | €0.47 | -5.68% | 37.3M | -0.40 | -€1.23 | N/A |
| MKEA.PA | €0.62 | +0.32% | 30.2M | -2.49 | -€0.25 | N/A |
Stock Comparison
IBAB.BR vs PHIA.AS Comparison April 2026
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 371M. In comparison, PHIA.AS has a market cap of 22.3B. Regarding current trading prices, IBAB.BR is priced at €12.88, while PHIA.AS trades at €23.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 21.83, whereas PHIA.AS's P/E ratio is 25.25. In terms of profitability, IBAB.BR's ROE is +0.15%, compared to PHIA.AS's ROE of +0.08%. Regarding short-term risk, IBAB.BR is more volatile compared to PHIA.AS. This indicates potentially higher risk in terms of short-term price fluctuations for IBAB.BR.Check PHIA.AS's competition here
IBAB.BR vs ALERS.PA Comparison April 2026
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 371M. In comparison, ALERS.PA has a market cap of 223M. Regarding current trading prices, IBAB.BR is priced at €12.88, while ALERS.PA trades at €22.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 21.83, whereas ALERS.PA's P/E ratio is 100.68. In terms of profitability, IBAB.BR's ROE is +0.15%, compared to ALERS.PA's ROE of +0.01%. Regarding short-term risk, IBAB.BR is less volatile compared to ALERS.PA. This indicates potentially lower risk in terms of short-term price fluctuations for IBAB.BR.Check ALERS.PA's competition here
IBAB.BR vs ALMDT.PA Comparison April 2026
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 371M. In comparison, ALMDT.PA has a market cap of 161.7M. Regarding current trading prices, IBAB.BR is priced at €12.88, while ALMDT.PA trades at €4.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 21.83, whereas ALMDT.PA's P/E ratio is -3.71. In terms of profitability, IBAB.BR's ROE is +0.15%, compared to ALMDT.PA's ROE of +0.59%. Regarding short-term risk, IBAB.BR is less volatile compared to ALMDT.PA. This indicates potentially lower risk in terms of short-term price fluctuations for IBAB.BR.Check ALMDT.PA's competition here
IBAB.BR vs ALCOR.PA Comparison April 2026
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 371M. In comparison, ALCOR.PA has a market cap of 154.5M. Regarding current trading prices, IBAB.BR is priced at €12.88, while ALCOR.PA trades at €35.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 21.83, whereas ALCOR.PA's P/E ratio is -234.00. In terms of profitability, IBAB.BR's ROE is +0.15%, compared to ALCOR.PA's ROE of -0.23%. Regarding short-term risk, IBAB.BR is more volatile compared to ALCOR.PA. This indicates potentially higher risk in terms of short-term price fluctuations for IBAB.BR.Check ALCOR.PA's competition here
IBAB.BR vs GBT.PA Comparison April 2026
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 371M. In comparison, GBT.PA has a market cap of 123.5M. Regarding current trading prices, IBAB.BR is priced at €12.88, while GBT.PA trades at €9.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 21.83, whereas GBT.PA's P/E ratio is -1.10. In terms of profitability, IBAB.BR's ROE is +0.15%, compared to GBT.PA's ROE of -0.34%. Regarding short-term risk, IBAB.BR is more volatile compared to GBT.PA. This indicates potentially higher risk in terms of short-term price fluctuations for IBAB.BR.Check GBT.PA's competition here
IBAB.BR vs EAPI.PA Comparison April 2026
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 371M. In comparison, EAPI.PA has a market cap of 119.2M. Regarding current trading prices, IBAB.BR is priced at €12.88, while EAPI.PA trades at €1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 21.83, whereas EAPI.PA's P/E ratio is -0.96. In terms of profitability, IBAB.BR's ROE is +0.15%, compared to EAPI.PA's ROE of -0.24%. Regarding short-term risk, IBAB.BR is more volatile compared to EAPI.PA. This indicates potentially higher risk in terms of short-term price fluctuations for IBAB.BR.Check EAPI.PA's competition here
IBAB.BR vs AFME.PA Comparison April 2026
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 371M. In comparison, AFME.PA has a market cap of 110.4M. Regarding current trading prices, IBAB.BR is priced at €12.88, while AFME.PA trades at €2.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 21.83, whereas AFME.PA's P/E ratio is -7.81. In terms of profitability, IBAB.BR's ROE is +0.15%, compared to AFME.PA's ROE of -0.57%. Regarding short-term risk, IBAB.BR is less volatile compared to AFME.PA. This indicates potentially lower risk in terms of short-term price fluctuations for IBAB.BR.Check AFME.PA's competition here
IBAB.BR vs SEQUA.BR Comparison April 2026
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 371M. In comparison, SEQUA.BR has a market cap of 37.3M. Regarding current trading prices, IBAB.BR is priced at €12.88, while SEQUA.BR trades at €0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 21.83, whereas SEQUA.BR's P/E ratio is -0.40. In terms of profitability, IBAB.BR's ROE is +0.15%, compared to SEQUA.BR's ROE of +1.24%. Regarding short-term risk, IBAB.BR is less volatile compared to SEQUA.BR. This indicates potentially lower risk in terms of short-term price fluctuations for IBAB.BR.Check SEQUA.BR's competition here
IBAB.BR vs MKEA.PA Comparison April 2026
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 371M. In comparison, MKEA.PA has a market cap of 30.2M. Regarding current trading prices, IBAB.BR is priced at €12.88, while MKEA.PA trades at €0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 21.83, whereas MKEA.PA's P/E ratio is -2.49. In terms of profitability, IBAB.BR's ROE is +0.15%, compared to MKEA.PA's ROE of +0.74%. Regarding short-term risk, IBAB.BR is more volatile compared to MKEA.PA. This indicates potentially higher risk in terms of short-term price fluctuations for IBAB.BR.Check MKEA.PA's competition here
IBAB.BR vs ALIMP.PA Comparison April 2026
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 371M. In comparison, ALIMP.PA has a market cap of 29.2M. Regarding current trading prices, IBAB.BR is priced at €12.88, while ALIMP.PA trades at €0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 21.83, whereas ALIMP.PA's P/E ratio is -5.07. In terms of profitability, IBAB.BR's ROE is +0.15%, compared to ALIMP.PA's ROE of +13.76%. Regarding short-term risk, IBAB.BR is less volatile compared to ALIMP.PA. This indicates potentially lower risk in terms of short-term price fluctuations for IBAB.BR.Check ALIMP.PA's competition here
IBAB.BR vs ALDMS.PA Comparison April 2026
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 371M. In comparison, ALDMS.PA has a market cap of 28M. Regarding current trading prices, IBAB.BR is priced at €12.88, while ALDMS.PA trades at €1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 21.83, whereas ALDMS.PA's P/E ratio is -10.31. In terms of profitability, IBAB.BR's ROE is +0.15%, compared to ALDMS.PA's ROE of -0.13%. Regarding short-term risk, IBAB.BR is more volatile compared to ALDMS.PA. This indicates potentially higher risk in terms of short-term price fluctuations for IBAB.BR.Check ALDMS.PA's competition here
IBAB.BR vs ALNOV.PA Comparison April 2026
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 371M. In comparison, ALNOV.PA has a market cap of 27.5M. Regarding current trading prices, IBAB.BR is priced at €12.88, while ALNOV.PA trades at €0.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 21.83, whereas ALNOV.PA's P/E ratio is -0.83. In terms of profitability, IBAB.BR's ROE is +0.15%, compared to ALNOV.PA's ROE of -0.15%. Regarding short-term risk, IBAB.BR is more volatile compared to ALNOV.PA. This indicates potentially higher risk in terms of short-term price fluctuations for IBAB.BR.Check ALNOV.PA's competition here
IBAB.BR vs ALIKO.PA Comparison April 2026
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 371M. In comparison, ALIKO.PA has a market cap of 22.9M. Regarding current trading prices, IBAB.BR is priced at €12.88, while ALIKO.PA trades at €1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 21.83, whereas ALIKO.PA's P/E ratio is -6.30. In terms of profitability, IBAB.BR's ROE is +0.15%, compared to ALIKO.PA's ROE of -0.17%. Regarding short-term risk, IBAB.BR is more volatile compared to ALIKO.PA. This indicates potentially higher risk in terms of short-term price fluctuations for IBAB.BR.Check ALIKO.PA's competition here
IBAB.BR vs ALTHE.PA Comparison April 2026
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 371M. In comparison, ALTHE.PA has a market cap of 21.1M. Regarding current trading prices, IBAB.BR is priced at €12.88, while ALTHE.PA trades at €0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 21.83, whereas ALTHE.PA's P/E ratio is -4.07. In terms of profitability, IBAB.BR's ROE is +0.15%, compared to ALTHE.PA's ROE of +4.68%. Regarding short-term risk, IBAB.BR is more volatile compared to ALTHE.PA. This indicates potentially higher risk in terms of short-term price fluctuations for IBAB.BR.Check ALTHE.PA's competition here
IBAB.BR vs ALTER.PA Comparison April 2026
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 371M. In comparison, ALTER.PA has a market cap of 17.3M. Regarding current trading prices, IBAB.BR is priced at €12.88, while ALTER.PA trades at €1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 21.83, whereas ALTER.PA's P/E ratio is 42.00. In terms of profitability, IBAB.BR's ROE is +0.15%, compared to ALTER.PA's ROE of -0.06%. Regarding short-term risk, IBAB.BR is less volatile compared to ALTER.PA. This indicates potentially lower risk in terms of short-term price fluctuations for IBAB.BR.Check ALTER.PA's competition here
IBAB.BR vs ALEMG.PA Comparison April 2026
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 371M. In comparison, ALEMG.PA has a market cap of 13.2M. Regarding current trading prices, IBAB.BR is priced at €12.88, while ALEMG.PA trades at €4.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 21.83, whereas ALEMG.PA's P/E ratio is 12.24. In terms of profitability, IBAB.BR's ROE is +0.15%, compared to ALEMG.PA's ROE of -0.33%. Regarding short-term risk, IBAB.BR is more volatile compared to ALEMG.PA. This indicates potentially higher risk in terms of short-term price fluctuations for IBAB.BR.Check ALEMG.PA's competition here
IBAB.BR vs ALBLU.PA Comparison April 2026
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 371M. In comparison, ALBLU.PA has a market cap of 8.5M. Regarding current trading prices, IBAB.BR is priced at €12.88, while ALBLU.PA trades at €0.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 21.83, whereas ALBLU.PA's P/E ratio is -7.70. In terms of profitability, IBAB.BR's ROE is +0.15%, compared to ALBLU.PA's ROE of -0.71%. Regarding short-term risk, IBAB.BR is less volatile compared to ALBLU.PA. This indicates potentially lower risk in terms of short-term price fluctuations for IBAB.BR.Check ALBLU.PA's competition here
IBAB.BR vs ALSGD.PA Comparison April 2026
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 371M. In comparison, ALSGD.PA has a market cap of 7.2M. Regarding current trading prices, IBAB.BR is priced at €12.88, while ALSGD.PA trades at €0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 21.83, whereas ALSGD.PA's P/E ratio is -2.89. In terms of profitability, IBAB.BR's ROE is +0.15%, compared to ALSGD.PA's ROE of -0.63%. Regarding short-term risk, IBAB.BR is less volatile compared to ALSGD.PA. This indicates potentially lower risk in terms of short-term price fluctuations for IBAB.BR.Check ALSGD.PA's competition here
IBAB.BR vs ALCAR.PA Comparison April 2026
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 371M. In comparison, ALCAR.PA has a market cap of 6.4M. Regarding current trading prices, IBAB.BR is priced at €12.88, while ALCAR.PA trades at €0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 21.83, whereas ALCAR.PA's P/E ratio is -0.09. In terms of profitability, IBAB.BR's ROE is +0.15%, compared to ALCAR.PA's ROE of +1.07%. Regarding short-term risk, IBAB.BR is less volatile compared to ALCAR.PA. This indicates potentially lower risk in terms of short-term price fluctuations for IBAB.BR.Check ALCAR.PA's competition here
IBAB.BR vs DGM.PA Comparison April 2026
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 371M. In comparison, DGM.PA has a market cap of 0. Regarding current trading prices, IBAB.BR is priced at €12.88, while DGM.PA trades at €1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 21.83, whereas DGM.PA's P/E ratio is -4.43. In terms of profitability, IBAB.BR's ROE is +0.15%, compared to DGM.PA's ROE of -0.23%. Regarding short-term risk, IBAB.BR is less volatile compared to DGM.PA. This indicates potentially lower risk in terms of short-term price fluctuations for IBAB.BR.Check DGM.PA's competition here
IBAB.BR vs VMGBS.PA Comparison April 2026
IBAB.BR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IBAB.BR stands at 371M. In comparison, VMGBS.PA has a market cap of 0. Regarding current trading prices, IBAB.BR is priced at €12.88, while VMGBS.PA trades at €0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IBAB.BR currently has a P/E ratio of 21.83, whereas VMGBS.PA's P/E ratio is N/A. In terms of profitability, IBAB.BR's ROE is +0.15%, compared to VMGBS.PA's ROE of N/A. Regarding short-term risk, IBAB.BR is more volatile compared to VMGBS.PA. This indicates potentially higher risk in terms of short-term price fluctuations for IBAB.BR.Check VMGBS.PA's competition here